title: Review: smoking cessation strategies in patients with lung disease.
abstract: BACKGROUND
  Smoking is related to a great variety of pathological conditions, many of which affect the respiratory system, such as lung cancer and chronic obstructive pulmonary disease (COPD). Smoking cessation should be an integral part of the therapeutic approach to patients with pulmonary disease.
  
  
  OBJECTIVE
  The objective was to provide a systematic review of the efficacy of the various treatments for smoking cessation in patients with diagnosed pulmonary disease.
  
  
  METHODS
  We conducted a search in the PubMed database in order to find studies related to the efficiency of smoking cessation treatments for this group of patients. Studies with confusing or no data on outcome and follow-up, and studies which did not use validated techniques were excluded.
  
  
  RESULTS
  The current treatment options include pharmaceutical therapies (bupropion, varenicline, etc) and counselling techniques. In the few trials that have been conducted, both approaches seem to be effective for treating tobacco dependence, with even higher abstinence rates, when combined.
  
  
  CONCLUSIONS
  Despite the promising results, more research is necessary, especially in patients with lung cancer, in order to determine the most beneficial smoking cessation treatment for each group of patients.
authors: Oncology Unit GPP, Sotiria General Hospital, Athens Medical School, 152 Mesogeion, Athens, 115 27, Greece. ksyrigos@med.uoa.gr
authors: Georgia
authors: G
authors: Tsiapa
authors: Ioannis
authors: I
authors: Gkiozos
authors: Kyriakos
authors: K
authors: Souliotis
authors: Kostas
authors: K
authors: Syrigos
mesh_terms: D001552:Benzazepines / Q000627:therapeutic use*; D016642:Bupropion / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D037001:Directive Counseling; D006801:Humans; D008171:Lung Diseases / Q000150:complications / Q000628:therapy*; D018733:Nicotinic Antagonists / Q000627:therapeutic use*; D039781:PubMed; D011810:Quinoxalines / Q000627:therapeutic use*; D016540:Smoking Cessation / Q000379:methods*; D061485:Tobacco Use Cessation Devices; D016896:Treatment Outcome; D000068580:Varenicline
chemical_list: D001552:Benzazepines; D018733:Nicotinic Antagonists; D011810:Quinoxalines; D016642:Bupropion; D000068580:Varenicline